Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Research analysts at Stifel Canada reduced their Q3 2024 earnings per share estimates for shares of Cipher Pharmaceuticals in a report released on Tuesday, October 22nd. Stifel Canada analyst J. Keywood now expects that the company will earn $0.03 per share for the quarter, down from their previous forecast of $0.27. Stifel Canada currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.65 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ FY2024 earnings at $0.72 EPS.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last posted its quarterly earnings results on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.01. The firm had revenue of C$7.26 million for the quarter, compared to analysts’ expectations of C$7.52 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%.
Get Our Latest Stock Analysis on CPH
Cipher Pharmaceuticals Price Performance
CPH stock opened at C$16.52 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67. The company’s 50-day moving average is C$16.45 and its 200-day moving average is C$11.80. The stock has a market capitalization of C$422.75 million, a PE ratio of 13.32 and a beta of 1.20. Cipher Pharmaceuticals has a 1 year low of C$4.30 and a 1 year high of C$19.69.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is an Earnings Surprise?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.